Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PEP-CMV Vaccine

Vaccine (Peptide vaccine) · Immune activation, directed at cytomegalovirus antigens

Phase 1/2 Most advanced trial (none active)

What is PEP-CMV Vaccine?

PEP-CMV is a peptide vaccine derived from cytomegalovirus antigens. Intradermal administration is intended to stimulate helper and cytotoxic T-lymphocyte responses against CMV-infected tumor cells. It is studied in diffuse midline glioma, medulloblastoma and ependymoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
cytomegalovirus antigens (antigen)
Mechanism
Immune activation, directed at cytomegalovirus antigens
Pathways
helper T-cell response, cytotoxic T-lymphocyte response
Therapy area
Oncology
In trials of
BMY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Diffuse Midline GliomaDiffuse Midline High-grade GliomaEpendymomaMedulloblastoma

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.